Novartis | NOVN - Selling And Administration Expenses


Novartis reported $3.44B in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alcon AG USD 901M 36M Dec/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Autolus Therapeutics Ltd USD 35.79M 1.68M Dec/2025
Bayer EUR 4.05B 647M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Fresenius EUR 819M 143M Dec/2025
Fresenius Medical Care EUR 785M 79.56M Dec/2025
Galapagos EUR 44.42M 9.87M Dec/2025
Genmab DKK 208M 60M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GRIFOLS EUR 275.3M 9.7M Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
J&J USD 6.75B 831M Dec/2025
Merck EUR 1.6B 136M Dec/2025
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Novo Nordisk DKK 17.44B 1.41B Dec/2025
Orion EUR 110.7M 26.1M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Philips EUR 1.31B 127M Dec/2025
Recordati EUR 171.38M 15.6M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.47B 193M Dec/2025